Amgen
Search results
Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while ...
Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while ...
Biogen was founded in 1978 in Geneva as Biotechnology Geneva by several prominent biologists, including Kenneth Murray from the University of Edinburgh, Phillip Allen Sharp from the Massachusetts Institute of Technology, Walter Gilbert from Harvard University (Gilbert served as CEO during the start-up phase of Biogen), Heinz Schaller ...
Jan 31, 2024 · Our medicines aim to improve the well-being of people around the world. Our Products Below is a list of our company's therapies. The below information is intended for U.S. residents only. For product information for other countries, please visit your country's Biogen affiliate website.
Jun 7, 2021 · FDA approves Biogen Alzheimer’s treatment. It is a reflection of “two decades of no innovation” and will also allow the company to further invest in its pipeline of drugs for other diseases ...
Jun 14, 2021 · Biogen’s Aduhelm (aducanumab) targets the plaques that contribute to the cognition decline seen in dementia. The infusion has divided the scientific community over its effectiveness, while research is still ongoing.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.
May 22, 2024 · Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences. May 22, 2024. PDF Version. Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated diseases.
Jun 8, 2021 · U.S. regulators on Monday approved Biogen Inc's (BIIB.O) aducanumab as the first treatment to attack a likely cause of Alzheimer's disease despite controversy over whether the clinical evidence...
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our ...
